JINARC® (Tolvaptan) Launch Event

Privacy Statement:
We collect personal information about you when you interact with us. We use this information to provide information about our products and stay in contact with you. You can find out more about the ways in which we use, handle and store personal information and how you can access your information at https://otsuka.com.au/privacy-policy/

JINARC® Prescription Medicine (tolvaptan tablets). JINARC is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease (CKD) stage 1 to 4 at initiation of treatment with evidence of rapidly progressing disease. Before prescribing JINARC, please refer to the full Data Sheet for information on dosage, contraindications, precautions, interactions and adverse effects. Because of the risk of liver injury, prescriber education and certification on the risk of liver injury and the importance of regular liver function monitoring is mandatory. These are available through the IMADJIN® Program, which is run and maintained by, or for, Otsuka Australia Pharmaceutical Pty. Ltd. Further information on the IMADJIN® Program is available at www.jinarc.co.nz or by telephone at 0800 602 200. Date of Preparation of TAPS Mandatories: 23 Sep 2022

JINARC® is not currently funded in New Zealand. Review full Data Sheet before prescribing. Approved Data Sheet is available from Otsuka Australia Pharmaceutical Pty Ltd Ph 0800 602 200 or at https://www.medsafe.govt.nz/Profs/Datasheet/j/jinarctabcomb.pdf . JINARC® is a registered trademark of Otsuka Pharmaceutical Co., Ltd. IMADJIN® is a registered trademark of Otsuka Australia Pharmaceutical Pty Ltd. Otsuka Australia Pharmaceutical Pty Ltd. Sponsor: Pharmacy Retailing (NZ) Limited, t/a Healthcare Logistics 58 Richard Pearse Drive, Airport Oaks, Mangere 2022, Auckland, New Zealand.

TAPS NP18626

Date of Preparation: October 2022. JIN-NZ-15